Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
961 participants
INTERVENTIONAL
2005-09-30
2006-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery
NCT00398216
Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
NCT00396786
inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT
NCT06581965
Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
NCT00371683
Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery
NCT00306254
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
PREVENTION
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Odiparcil
Warfarin
Coumadin
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Will have a total knee replacement.
Exclusion Criteria
* Allergies or reactions to warfarin or coumadin.
* Previous VTE (venous thromboembolism) or deep vein thrombosis (DVT).
* On anticoagulation therapy.
* Renal impairment.
* Participated in any clinical trial in the past 30 days.
35 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Mobile, Alabama, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Little Rock, Arkansas, United States
GSK Investigational Site
Banning, California, United States
GSK Investigational Site
Sacramento, California, United States
GSK Investigational Site
Torrance, California, United States
GSK Investigational Site
Yuba City, California, United States
GSK Investigational Site
Colorado Springs, Colorado, United States
GSK Investigational Site
Lonetree, Colorado, United States
GSK Investigational Site
Clearwater, Florida, United States
GSK Investigational Site
DeLand, Florida, United States
GSK Investigational Site
Jacksonville, Florida, United States
GSK Investigational Site
Sarasota, Florida, United States
GSK Investigational Site
Sarsota, Florida, United States
GSK Investigational Site
St. Petersburg, Florida, United States
GSK Investigational Site
Decatur, Georgia, United States
GSK Investigational Site
Boise, Idaho, United States
GSK Investigational Site
Lexington, Kentucky, United States
GSK Investigational Site
Baton Rouge, Louisiana, United States
GSK Investigational Site
Baltimore, Maryland, United States
GSK Investigational Site
Baltimore, Maryland, United States
GSK Investigational Site
Baltimore, Maryland, United States
GSK Investigational Site
Warren, Michigan, United States
GSK Investigational Site
Mineola, New York, United States
GSK Investigational Site
Charlotte, North Carolina, United States
GSK Investigational Site
Durham, North Carolina, United States
GSK Investigational Site
Cincinnati, Ohio, United States
GSK Investigational Site
Cleveland, Ohio, United States
GSK Investigational Site
Toledo, Ohio, United States
GSK Investigational Site
Allentown, Pennsylvania, United States
GSK Investigational Site
Altoona, Pennsylvania, United States
GSK Investigational Site
Camp Hill, Pennsylvania, United States
GSK Investigational Site
Hershey, Pennsylvania, United States
GSK Investigational Site
Philadelphia, Pennsylvania, United States
GSK Investigational Site
Philadelphia, Pennsylvania, United States
GSK Investigational Site
Dallas, Texas, United States
GSK Investigational Site
Dallas, Texas, United States
GSK Investigational Site
Lubbock, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
Norfolk, Virginia, United States
GSK Investigational Site
Richmond, Virginia, United States
GSK Investigational Site
Richmond, Virginia, United States
GSK Investigational Site
Huntington, West Virginia, United States
GSK Investigational Site
Marshfield, Wisconsin, United States
GSK Investigational Site
Camperdown, New South Wales, Australia
GSK Investigational Site
Southport, Queensland, Australia
GSK Investigational Site
Box Hill, Victoria, Australia
GSK Investigational Site
Clayton, Victoria, Australia
GSK Investigational Site
Geelong, Victoria, Australia
GSK Investigational Site
Ringwood East, Victoria, Australia
GSK Investigational Site
Windsor, Victoria, Australia
GSK Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
GSK Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
GSK Investigational Site
Winnipeg, Manitoba, Canada
GSK Investigational Site
Ajax, Ontario, Canada
GSK Investigational Site
Don Mills, Ontario, Canada
GSK Investigational Site
Newmarket, Ontario, Canada
GSK Investigational Site
North York, Ontario, Canada
GSK Investigational Site
Oshawa, Ontario, Canada
GSK Investigational Site
Scarborough Village, Ontario, Canada
GSK Investigational Site
Waterloo, Ontario, Canada
GSK Investigational Site
Charlottetown, Prince Edward Island, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Sainte Jerome, Quebec, Canada
GSK Investigational Site
Chennai, , India
GSK Investigational Site
Secunderabad, , India
GSK Investigational Site
Haifa, , Israel
GSK Investigational Site
Kfar Saba, , Israel
GSK Investigational Site
Petah Tikva, , Israel
GSK Investigational Site
Tel Aviv, , Israel
GSK Investigational Site
Riga, , Latvia
GSK Investigational Site
Riga, , Latvia
GSK Investigational Site
Kaunas, , Lithuania
GSK Investigational Site
Klaipėda, , Lithuania
GSK Investigational Site
Vilnius, , Lithuania
GSK Investigational Site
Bialystok, , Poland
GSK Investigational Site
Krakow, , Poland
GSK Investigational Site
Sosnowiec, , Poland
GSK Investigational Site
Wroclaw, , Poland
GSK Investigational Site
Irkutsk, , Russia
GSK Investigational Site
Kurgan, , Russia
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Mosocow, , Russia
GSK Investigational Site
Mosocow, , Russia
GSK Investigational Site
Rostov-on-Don, , Russia
GSK Investigational Site
Pretoria, Gauteng, South Africa
GSK Investigational Site
Centurion, , South Africa
GSK Investigational Site
Pretoria, , South Africa
GSK Investigational Site
Cherkasy, , Ukraine
GSK Investigational Site
Dnipro, , Ukraine
GSK Investigational Site
Kyiv, , Ukraine
GSK Investigational Site
Kyiv, , Ukraine
GSK Investigational Site
Vinnitsa, , Ukraine
GSK Investigational Site
Birmingham, West Midlands, United Kingdom
GSK Investigational Site
Bournmouth, , United Kingdom
GSK Investigational Site
Fife, , United Kingdom
GSK Investigational Site
London, , United Kingdom
GSK Investigational Site
Wigan, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ITI101711
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.